These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 30510441)

  • 1. The prognostic impact of neutrophil to lymphocyte ratio in advanced non-small cell lung cancer patients treated with EGFR TKI.
    Phan TT; Ho TT; Nguyen HT; Nguyen HT; Tran TB; Nguyen ST
    Int J Gen Med; 2018; 11():423-430. PubMed ID: 30510441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of neutrophil-to-lymphocyte ratio in patients with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors.
    Ono T; Igawa S; Kurahayashi S; Okuma Y; Sugimoto A; Kusuhara S; Ozawa T; Fukui T; Sasaki J; Mitsufuji H; Yokoba M; Kubota M; Katagiri M; Naoki K
    Invest New Drugs; 2020 Jun; 38(3):885-893. PubMed ID: 32157598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased monocyte-to-lymphocyte ratio was associated with satisfied outcomes of first-line PD-1 inhibitors plus chemotherapy in stage IIIB-IV non-small cell lung cancer.
    Zheng L; Xiong A; Wang S; Xu J; Shen Y; Zhong R; Lu J; Chu T; Zhang W; Li Y; Zheng X; Han B; Zhong H; Nie W; Zhang X
    Front Immunol; 2023; 14():1094378. PubMed ID: 36776882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pretreatment neutrophil-to-lymphocyte ratio is a predictive biomarker for EGFR TKI-treated patients with advanced EGFR-mutant Non-small cell lung cancer.
    Xu C; Yao X; Li T; Wang J; An B; Wang J; Sui X; Leung EL; Wu Q
    Transl Cancer Res; 2020 Apr; 9(4):2875-2883. PubMed ID: 35117644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
    Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
    J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The peripheral blood neutrophil-to-lymphocyte ratio is a prognostic predictor for survival of EGFR-mutant nonsmall cell lung cancer patients treated with EGFR-TKIs.
    Zhang Y; Feng YC; Zhu HG; Xiong TC; Hou YS; Song J; Jiang W; Zhu CJ
    Medicine (Baltimore); 2018 Jul; 97(30):e11648. PubMed ID: 30045314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
    Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
    Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutrophil-to-Lymphocyte Ratio Predicts Overall Survival of Advanced Non-Small Cell Lung Cancer Harboring Mutant Epidermal Growth Factor Receptor.
    Minami S; Ogata Y; Ihara S; Yamamoto S; Komuta K
    World J Oncol; 2017 Dec; 8(6):180-187. PubMed ID: 29317963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutrophil-to-Lymphocyte Ratio Is a Predictive Biomarker in Patients with Epidermal Growth Factor Receptor (EGFR) Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Tyrosine Kinase Inhibitor (TKI) Therapy.
    Yun NK; Rouhani SJ; Bestvina CM; Ritz EM; Gilmore BA; Tarhoni I; Borgia JA; Batus M; Bonomi PD; Fidler MJ
    Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33804721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?
    Deng M; Ma X; Liang X; Zhu C; Wang M
    Oncotarget; 2017 Jun; 8(23):37200-37207. PubMed ID: 28380461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood cell parameters as prognostic predictors of disease development for patients with advanced non-small cell lung cancer.
    Wang L; Si H; Wang J; Feng L; Zhai W; Dong S; Yu Z
    Oncol Lett; 2020 Aug; 20(2):1101-1110. PubMed ID: 32724349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of peripheral blood biomarkers with clinical outcomes in NSCLC patients with high PD-L1 expression treated with pembrolizumab.
    Sánchez-Gastaldo A; Muñoz-Fuentes MA; Molina-Pinelo S; Alonso-García M; Boyero L; Bernabé-Caro R
    Transl Lung Cancer Res; 2021 Jun; 10(6):2509-2522. PubMed ID: 34295658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors.
    Chen YM; Lai CH; Rau KM; Huang CH; Chang HC; Chao TY; Tseng CC; Fang WF; Chung YH; Wang YH; Su MC; Huang KT; Liu SF; Chen HC; Chang YC; Chang YP; Wang CC; Lin MC
    BMC Cancer; 2016 Nov; 16(1):868. PubMed ID: 27821111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio associations with heart and body dose and their effects on patient outcomes in locally advanced non-small cell lung cancer treated with definitive radiotherapy.
    Xia WY; Zhu XR; Feng W; Liu J; Wang JM; Lv CX; Zhang Q; Yu W; Cai XW; Fu XL
    Transl Lung Cancer Res; 2020 Oct; 9(5):1996-2007. PubMed ID: 33209619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic role of dynamic changes in inflammatory indicators in patients with non-small cell lung cancer treated with immune checkpoint inhibitors-a retrospective cohort study.
    Guo L; Li J; Wang J; Chen X; Cai C; Zhou F; Xiong A
    Transl Lung Cancer Res; 2024 Aug; 13(8):1975-1987. PubMed ID: 39263031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic Inflammatory Markers of Survival in Epidermal Growth Factor-Mutated Non-Small-Cell Lung Cancer: Single-Institution Analysis, Systematic Review, and Meta-analysis.
    Chan SWS; Smith E; Aggarwal R; Balaratnam K; Chen R; Hueniken K; Fazelzad R; Weiss J; Jiang S; Shepherd FA; Bradbury PA; Sacher AG; Leighl NB; Xu W; Brown MC; Eng L; Liu G
    Clin Lung Cancer; 2021 Sep; 22(5):390-407. PubMed ID: 33582072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated pretreatment neutrophil/white blood cell ratio and monocyte/lymphocyte ratio predict poor survival in patients with curatively resected non-small cell lung cancer: Results from a large cohort.
    Yuan C; Li N; Mao X; Liu Z; Ou W; Wang SY
    Thorac Cancer; 2017 Jul; 8(4):350-358. PubMed ID: 28544400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes in patients with advanced epidermal growth factor receptor-mutated non-small-cell lung cancer in South Western Sydney Local Health District.
    Ding PN; Roberts TL; Chua W; Becker TM; Descallar J; Yip PY; Bray V
    Intern Med J; 2017 Dec; 47(12):1405-1411. PubMed ID: 28742280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio is a useful prognostic factor in advanced non-small cell lung cancer patients.
    Wu G; Yao Y; Bai C; Zeng J; Shi D; Gu X; Shi X; Song Y
    Thorac Cancer; 2015 May; 6(3):275-87. PubMed ID: 26273373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can Neutrophil-to-Lymphocyte Ratio, Monocyte-to-Lymphocyte Ratio, and Platelet-to-Lymphocyte Ratio at Day +100 be used as a prognostic marker in Multiple Myeloma patients with autologous transplantation?
    Solmaz Medeni S; Acar C; Olgun A; Acar A; Seyhanlı A; Taskıran E; Sevindik OG; Alacacıoglu I; Piskin O; Ozcan MA; Demirkan F; Undar B; Ozsan GH
    Clin Transplant; 2018 Sep; 32(9):e13359. PubMed ID: 30053318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.